Citations

Clear

367 citation(s) found for "Du, Pan".

Chapter 3 Motor Circuit Activity in Parkinson’s Disease
Bieber, Allan J.

Mayo Clinic

Deep Brain Stimulation | December 2, 2016 | Volume: No volume available | Issue: No issue available | Pages: 51-66

10.1201/9781315364759-4 Get It

Chapter 20 Electrodes for Neural Stimulation and Monitoring
Tomshine, Jonathan R. , Bennet, Kevin E.

Mayo Clinic

Deep Brain Stimulation | December 2, 2016 | Volume: No volume available | Issue: No issue available | Pages: 373-388

10.1201/9781315364759-21 Get It

Chapter 19 Electrochemical Measurement of Neurochemical Concentrations
Bennet, Kevin E. , Lee, Kendall H. , Blaha, Charles D.

Mayo Clinic

Deep Brain Stimulation | December 2, 2016 | Volume: No volume available | Issue: No issue available | Pages: 357-372

10.1201/9781315364759-20 Get It

Chapter 1 Overview of the History and Application of Deep Brain Stimulation
Lee, Kendall H. , Duffy, Penelope S., Blaha, Charles D.

Mayo Clinic

Deep Brain Stimulation | December 2, 2016 | Volume: No volume available | Issue: No issue available | Pages: 1-24

10.1201/9781315364759-2 Get It

Chapter 13 Deep Brain Stimulation for Medically Refractory Epilepsy
Gibson, William S. , Duffy, Penelope S.

Mayo Clinic

Deep Brain Stimulation | December 2, 2016 | Volume: No volume available | Issue: No issue available | Pages: 231-256

10.1201/9781315364759-14 Get It

A phase IIa study of afuresertib, an oral pan‐AKT inhibitor, in patients with Langerhans cell histiocytosis
Arceci, R.J., Allen, Carl E. , Jacobsen, Eric D. , Whitlock, James A. , Vassallo, Robert , Morris, Shannon R., Portnoy, Alison, Reedy, Beth Ann, Smith, Deborah A. , Noble, Robert, Murnane, Amy A., Cornfeld, Mark, Heaney, Mark , McClain, Kenneth L. , Vaiselbuh, Sarah R., Dunkel, Ira J. , Rodríguez‐Galindo, Carlos , Vassallo, Robert , McClain, Kenneth L , Allen, Carl E

Mayo Clinic

Pediatric Blood & Cancer | November 2, 2016 | Volume: 64 | Issue: 5 | Pages: No page available

10.1002/pbc.26325 | PMID 27804235 Get It

AbstractBackgroundLangerhans cell histiocytosis (LCH) is a clonal neoplasm characterized by widely varied clinical presentations, including multisystem involvement and systemic inflammatory symptoms. The AKT pathway is relevant to survival and proliferation of dendritic cells, and is also often upregulated in hematopoietic malignancies. A clinical response in an adult patient with LCH participating in the first‐in‐human trial of afuresertib prompted this prospective trial.ProcedureThe population in the current study included treatment‐naïve (n = 7) and recurrent/refractory patients with LCH (n = 10), who received oral afuresertib (125 mg). The majority of patients were treated for > 24 weeks, with four patients receiving treatment for > 48 weeks.ResultsPharmacokinetic analysis showed similar exposures in previously reported patients with other hematologic malignancies. Primary drug‐related toxicities included Grade 1/2 nausea, diarrhea, dyspepsia, and vomiting. Grade 3 toxicities included fatigue, diarrhea, and pain (one of each). Another severe adverse event involved soft tissue necrosis. The overall response rate in evaluable subjects was 33% in treatment‐naïve patients and 28% in patients with recurrent/refractory disease, which did not meet the predefined Bayesian criteria for efficacy.ConclusionAfuresertib has clinical activity in some patients with newly diagnosed and advanced LCH.
Expression profiling and ontology analysis of circulating long non-coding RNAs in septic acute kidney injury patients
Huang, Chunmei , Ge, Qinmin , Shuming, Pan, Zhu, Xiangyang , Shu-Ming, Pan

Mayo Clinic

Clinical Chemistry and Laboratory Medicine (CCLM) | June 25, 2016 | Volume: 54 | Issue: 12 | Pages: e395-e399

10.1515/cclm-2015-1281 | PMID 27341563 Get It

Predicting regulatory variants with composite statistic
Li, Mulin Jun , Liu, Zipeng , Wu, Jiexing , Wang, Panwen , Zhu, Yun , Xia, Zhengyuan , Sham, Pak C. , Kocher, Jean-Pierre A., Liu, Jun S. , Li, Miaoxin, Wang, Junwen , Pan, Zhicheng , Xu, Feng , Kocher, Jean-Pierre A., Wang, Junwen , Xia, Zhengyuan

Mayo Clinic

Bioinformatics | June 7, 2016 | Volume: 32 | Issue: 18 | Pages: 2729-2736

10.1093/bioinformatics/btw288 | PMID 27273672 Get It

Abstract Motivation: Prediction and prioritization of human non-coding regulatory variants is critical for understanding the regulatory mechanisms of disease pathogenesis and promoting personalized medicine. Existing tools utilize functional genomics data and evolutionary information to evaluate the pathogenicity or regulatory functions of non-coding variants. However, different algorithms lead to inconsistent and even conflicting predictions. Combining multiple methods may increase accuracy in regulatory variant prediction. Results: Here, we compiled an integrative resource for predictions from eight different tools on functional annotation of non-coding variants. We further developed a composite strategy to integrate multiple predictions and computed the composite likelihood of a given variant being regulatory variant. Benchmarked by multiple independent causal variants datasets, we demonstrated that our composite model significantly improves the prediction performance. Availability and Implementation: We implemented our model and scoring procedure as a tool, named PRVCS, which is freely available to academic and non-profit usage at http://jjwanglab.org/PRVCS. Contact: wang.junwen@mayo.edu, jliu@stat.harvard.edu, or limx54@gmail.com Supplementary information: Supplementary data are available at Bioinformatics online.
JNK2 downregulation promotes tumorigenesis and chemoresistance by decreasing p53 stability in bladder cancer
Pan, Chun-Wu, Liu, Hailong , Qian, Chenchen , Wang, Liguo , Qi, Jun , Zhao, Yu , Wang, Liguo

Mayo Clinic

Oncotarget | April 27, 2016 | Volume: 7 | Issue: 23 | Pages: 35119-35131

10.18632/oncotarget.9046 | PMID 27147566 Get It